Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
12:35pm, Friday, 01'st May 2026
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Revenue was $389 million. The analyst estimate was $130.62 million.GAAP EPS was -$3.40. The analyst estimate was -$2.17.Net loss was $(1.343) billion, includin
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
11:55am, Friday, 01'st May 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected net loss and missed earnings estimates due i
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook
10:58am, Friday, 01'st May 2026
Moderna (MRNA) delivered a strong 1Q26 revenue beat, driven by international COVID-19 vaccine sales, and reaffirmed 2026 guidance for up to 10% revenue growth. Cost discipline is improving, with R&D a
Moderna Sales Triple To $389 Million As Shares Rise 5.4%
10:55am, Friday, 01'st May 2026
Moderna (MRNA) reported first-quarter sales that came in ahead of expectations, giving investors a fresh signal that the vaccine maker may be finding growth out
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
08:45am, Friday, 01'st May 2026
Moderna (MRNA) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $2.52 per share a year ago.
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
07:53am, Friday, 01'st May 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected...
Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
07:46am, Friday, 01'st May 2026
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
Breakfast News: Atlassian Pops 25% On AI Power
07:30am, Friday, 01'st May 2026
Atlassian posts big Q1 gains, Reddit and Twilio beat expectations, and more
Moderna Reports Higher Revenue but Posts a Loss
06:37am, Friday, 01'st May 2026
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
06:32am, Friday, 01'st May 2026
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets.
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
06:30am, Friday, 01'st May 2026
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
07:21am, Thursday, 30'th Apr 2026
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund lau
This iShares ETF Beats Its Mid-Cap Rival on Price -- but Not on Stability
12:07pm, Wednesday, 29'th Apr 2026
Expense ratios, dividend yields, and portfolio composition reveal key differences between these two value-focused iShares funds.
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
11:05am, Wednesday, 29'th Apr 2026
I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise acr
